Announced Thu, 2 Jul · 16:28 IST
Routine compliance filing on share dematerialisation for Q1 FY27
Compliance View source PDF
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.0%1-day move
₹1563.00
prior close
₹1568.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+1.0+1.2+2.4+2.0+1.3-0.3+1.3+0.2-0.7-2.0———
Up moveDown movePending
AI summary
Aurobindo Pharma has submitted a quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The filing, signed by Company Secretary B. Adi Reddy along with certificates from RTA KFin Technologies sent to NSDL and CDSL, confirms that details of securities dematerialised and rematerialised during the quarter have been furnished to NSE and BSE. This is a standard periodic obligation with no business action involved.
Likely market impact
Routine regulatory compliance filing. No material impact on shareholders or stock price.